ANEURYST, INC.

Biotech · Private

Fasudil, a ROCK inhibitor molecule for treating cerebral vasospasm after subarachnoid hemorrhage

Grants
$492K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
5
1 granted · 4 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Enzyme phenotyping of hydroxyfasudil$492,110
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2604CHAPERONE THERAPEUTICS, INC.—$457K
2605CONCARLO HOLDINGS, LLC—$450K
2606GSNO THERAPEUTICS, INC.——
2607ANEURYST, INC.——
2608GABAeron, Inc.——
2609Curza Inc—$367K
2610BreStem Therapeutics, Inc.—$300K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 5
  • Treatments For Disturbed Cerebral Homeostasisgranted
  • Treatments For Disturbed Cerebral Homeostasisapplication
  • Treatments For Disturbed Cerebral Homeostasisapplication
  • Treatments For Disturbed Cerebral Homeostasisapplication
  • Treatments For Disturbed Cerebral Homeostasisapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.